FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1838162521> ?p ?o ?g. }

• W1838162521 endingPage "2146" @default.
• W1838162521 startingPage "2137" @default.
• W1838162521 abstract "Ideal vaccines should be stable, safe, molecularly defined, and out-of-shelf reagents efficient at triggering effector and memory Ag-specific T cell-based immune responses. Dendritic cell-derived exosomes could be considered as novel peptide-based vaccines because exosomes harbor a discrete set of proteins, bear functional MHC class I and II molecules that can be loaded with synthetic peptides of choice, and are stable reagents that were safely used in pioneering phase I studies. However, we showed in part I that exosomes are efficient to promote primary MHC class I-restricted effector CD8(+) T cell responses only when transferred onto mature DC in vivo. In this work, we bring evidence that among the clinically available reagents, Toll-like receptor 3 and 9 ligands are elective adjuvants capable of triggering efficient MHC-restricted CD8(+) T cell responses when combined to exosomes. Exosome immunogenicity across species allowed to verify the efficacy of good manufactory procedures-manufactured human exosomes admixed with CpG oligonucleotides in prophylactic and therapeutic settings of melanoma in HLA-A2 transgenic mice. CpG adjuvants appear to be ideal adjuvants for exosome-based cancer vaccines." @default.
• W1838162521 created "2016-06-24" @default.
• W1838162521 creator A5001814176 @default.
• W1838162521 creator A5015323424 @default.
• W1838162521 creator A5017494685 @default.
• W1838162521 creator A5024180743 @default.
• W1838162521 creator A5028371625 @default.
• W1838162521 creator A5028436035 @default.
• W1838162521 creator A5031362151 @default.
• W1838162521 creator A5037427764 @default.
• W1838162521 creator A5042753775 @default.
• W1838162521 creator A5044244232 @default.
• W1838162521 creator A5044270160 @default.
• W1838162521 creator A5047393976 @default.
• W1838162521 creator A5049672639 @default.
• W1838162521 creator A5054447772 @default.
• W1838162521 creator A5067917101 @default.
• W1838162521 creator A5070354041 @default.
• W1838162521 creator A5074612242 @default.
• W1838162521 creator A5090132643 @default.
• W1838162521 date "2004-02-15" @default.
• W1838162521 modified "2023-10-11" @default.
• W1838162521 title "Exosomes as Potent Cell-Free Peptide-Based Vaccine. II. Exosomes in CpG Adjuvants Efficiently Prime Naive Tc1 Lymphocytes Leading to Tumor Rejection" @default.
• W1838162521 cites W1483162601 @default.
• W1838162521 cites W1524792851 @default.
• W1838162521 cites W1536488163 @default.
• W1838162521 cites W1571520647 @default.
• W1838162521 cites W1606181274 @default.
• W1838162521 cites W1644577573 @default.
• W1838162521 cites W1655860314 @default.
• W1838162521 cites W1661544713 @default.
• W1838162521 cites W1669165205 @default.
• W1838162521 cites W1713603519 @default.
• W1838162521 cites W1731125787 @default.
• W1838162521 cites W1804501722 @default.
• W1838162521 cites W1934712179 @default.
• W1838162521 cites W1970847296 @default.
• W1838162521 cites W1977437107 @default.
• W1838162521 cites W1979132095 @default.
• W1838162521 cites W1984421836 @default.
• W1838162521 cites W1987508836 @default.
• W1838162521 cites W1994902503 @default.
• W1838162521 cites W1997384271 @default.
• W1838162521 cites W2002011994 @default.
• W1838162521 cites W2003444408 @default.
• W1838162521 cites W2005543808 @default.
• W1838162521 cites W2009509313 @default.
• W1838162521 cites W2025369716 @default.
• W1838162521 cites W2033598310 @default.
• W1838162521 cites W2035580952 @default.
• W1838162521 cites W2042373608 @default.
• W1838162521 cites W2047366876 @default.
• W1838162521 cites W2058881251 @default.
• W1838162521 cites W2076361525 @default.
• W1838162521 cites W2080879611 @default.
• W1838162521 cites W2091140484 @default.
• W1838162521 cites W2092128665 @default.
• W1838162521 cites W2092133085 @default.
• W1838162521 cites W2093284893 @default.
• W1838162521 cites W2102857621 @default.
• W1838162521 cites W2114737175 @default.
• W1838162521 cites W2117761826 @default.
• W1838162521 cites W2129651283 @default.
• W1838162521 cites W2131761283 @default.
• W1838162521 cites W2132552157 @default.
• W1838162521 cites W2135538358 @default.
• W1838162521 cites W2140944306 @default.
• W1838162521 cites W2148731066 @default.
• W1838162521 cites W2155229523 @default.
• W1838162521 cites W2155366992 @default.
• W1838162521 cites W2158500407 @default.
• W1838162521 cites W2159597545 @default.
• W1838162521 cites W2162076795 @default.
• W1838162521 cites W2167003108 @default.
• W1838162521 cites W2169035834 @default.
• W1838162521 cites W2177327503 @default.
• W1838162521 cites W2193208812 @default.
• W1838162521 doi "https://doi.org/10.4049/jimmunol.172.4.2137" @default.
• W1838162521 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14764679" @default.
• W1838162521 hasPublicationYear "2004" @default.
• W1838162521 type Work @default.
• W1838162521 sameAs 1838162521 @default.
• W1838162521 citedByCount "233" @default.
• W1838162521 countsByYear W18381625212012 @default.
• W1838162521 countsByYear W18381625212013 @default.
• W1838162521 countsByYear W18381625212014 @default.
• W1838162521 countsByYear W18381625212015 @default.
• W1838162521 countsByYear W18381625212016 @default.
• W1838162521 countsByYear W18381625212017 @default.
• W1838162521 countsByYear W18381625212018 @default.
• W1838162521 countsByYear W18381625212019 @default.
• W1838162521 countsByYear W18381625212020 @default.
• W1838162521 countsByYear W18381625212021 @default.
• W1838162521 countsByYear W18381625212022 @default.
• W1838162521 countsByYear W18381625212023 @default.
• W1838162521 crossrefType "journal-article" @default.
• W1838162521 hasAuthorship W1838162521A5001814176 @default.
• W1838162521 hasAuthorship W1838162521A5015323424 @default.

• next